State Street AUT UK Screened (ex Controversies and CW) Index EquityRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | -10.2 | 16.8 | -1.6 | 7.1 | 7.1 | |
+/-Cat | -1.1 | -1.2 | 0.5 | -1.1 | -0.3 | |
+/-B’mrk | - | - | - | -0.5 | -1.1 | |
Category: UK Large-Cap Equity | ||||||
Category Benchmark: Morningstar UK All Cap TME ... |
Key Stats | ||
NAV 20/11/2024 | GBP 3.26 | |
Day Change | -0.33% | |
Morningstar Category™ | UK Large-Cap Equity | |
IA (formerly IMA) Sector | UK All Companies | |
ISIN | GB00B06MWQ97 | |
Fund Size (Mil) 02/06/2020 | GBP 7739.32 | |
Share Class Size (Mil) 09/11/2021 | GBP 218.71 | |
Max Initial Charge | - | |
Ongoing Charge 02/02/2024 | 0.10% |
Investment Objective: State Street AUT UK Screened (ex Controversies and CW) Index Equity |
The Fund aims to replicate, as closely as possible and on a “gross‐of‐fees” basis, the return of the United Kingdom equity market as represented by the FTSE All‐Share ex Controversies ex CW Index, net of withholding taxes (or its recognised replacement or equivalent). |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Andrew Wright 30/04/2005 | ||
Inception Date 15/04/2005 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
FTSE AS x Cont x CW x Tob x The TR GBP | Morningstar UK All Cap TME NR GBP |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for State Street AUT UK Screened (ex Controversies and CW) Index Equity | 31/10/2024 |
|
|
Top 5 Holdings | Sector | % |
AstraZeneca PLC | Healthcare | 7.65 |
Shell PLC | Energy | 7.50 |
Unilever PLC | Consumer Defensive | 5.39 |
RELX PLC | Industrials | 3.07 |
BP PLC | Energy | 2.87 |
Increase Decrease New since last portfolio | ||
State Street AUT UK Screened (ex Controversies and CW) Index Equity |